巴雷特食管:当前面临的挑战  

Barrett’s esophagus:Current challenges in diagnosis and treatment

作　　者：劳上洪 黄纪乐 吴灵飞[1] Shang-Hong Lao;Ji-Le Huang;Ling-Fei Wu(Department of Gastroenterology,The Second Affiliated Hospital of Shantou University Medical College,Shantou 515041,Guangdong Province,China)

机构地区：[1]汕头大学医学院第二附属医院消化内科,广东省汕头市515041

出　　处：《世界华人消化杂志》2024年第4期267-275,共9页World Chinese Journal of Digestology

基　　金：2021年广东省自然科学基金项目,No.2021A1515012127.

摘　　要：近年来,无论在中国,亚太地区,还是西方国家,巴雷特食管(Barrett's esophagus,BE)的发病率均呈上升趋势,作为唯一已知的食管腺癌(esophageal adenocarcinoma,EAC)的癌前病变和最强风险因素,其漏诊率高,恶变为EAC后生存率低,其诊疗、筛查对于防治食管早癌具有非常重要的作用.但由于不同国家及地区的发病率不同,以及对此病的认识及重视程度各异,有关BE的诊断和治疗策略仍存在诸多争议.本文结合亚太、欧美BE诊治的最新指南,综述BE在当前诊断、检测及治疗方面的研究现状和挑战.In recent years,the incidence of Barrett’s esophagus(BE)has been increasing in China,the Asia-Pacific region,and Western countries.As the only known precancerous lesion and the strongest risk factor of esophageal adenocarcinoma(EAC),BE has a high rate of missed diagnosis and a low survival rate after malignant transformation into EAC.The diagnosis,treatment,and screening of BE play a very important role in the prevention and treatment of early esophageal cancer.However,due to the different incidence rates of BE in different countries and regions,as well as the different awareness and attention to this disease,there are still many controversies over its diagnosis and treatment.This article reviews the current research status and challenges in the diagnosis,detection,and treatment of BE based on the latest guidelines for Barrett’s esophagus diagnosis and treatment in the Asia-Pacific region,Europe,and America.

关 键 词：巴雷特食管 食管腺癌 内镜 肠化生 不典型增生 癌前病变 

分 类 号：R735.1[医药卫生—肿瘤]